Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial
scientific article published on 02 January 2020
Author/s
author: Piotr Rutkowski, Paul Lorigan, Alexander M. M. Eggermont, Stefan Suciu, Paolo Antonio Ascierto, Georgina V. Long, James Larkin, Christian U Blank, Dirk Schadendorf, Matteo Carlino
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.